Understanding how dexamethasone affects children with leukemia and their bone health
Official title: Pharmacokinetics of Dexamethasone in Childhood ALL and Reduction in Bone Mineral Density
Run by University of Aarhus · NCT06367725 · Data updated 2026-11-12
This study looks at how the medication dexamethasone affects bone health in children with leukemia by checking their bone density and medication levels over time.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 1 Year to 17 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | University of Aarhus Academic / other |
| Locations | 4 sites (Aalborg, Aalborg and 3 other locations) |
| Status | Recruiting |
| Started | April 11, 2024 |
| Main results expected | December 30, 2027 |
| Study ends | December 30, 2030 |
| Registry record updated | October 26, 2026 |
| Trial ID | NCT06367725 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are children aged 1 to 17.9 years who have been diagnosed with acute lymphoblastic leukemia.
✕Probably not a fit
Patients with Down syndrome will not benefit from this study as they are excluded from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to investigate the systemic exposure to dexamethasone in children diagnosed with acute lymphoblastic leukemia (ALL) and its correlation with bone mineral density. Participants will continue receiving standard therapy while providing blood and cerebrospinal fluid samples to measure dexamethasone levels. Additionally, they will undergo DXA scans at multiple time points to assess bone density and potential vertebral fractures. The study seeks to understand the relationship between dexamethasone exposure and bone health in this pediatric population.
Why it matters
Potential benefit: If successful, this study could lead to improved management of dexamethasone therapy in children with ALL, potentially reducing the risk of bone density loss.
How similar studies have gone: While this study focuses on a specific population and drug interaction, similar studies have shown the importance of monitoring medication effects on bone health in pediatric cancer patients.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * A diagnosis of acute lymphoblastic leukaemia * Age 1-17.9 years Exclusion Criteria: * Down syndrome
Where it's running
-
Department of Paediatrics and Adolescent Medicine, Aalborg University Hospital
Aalborg, Aalborg, Denmark Recruiting -
Department of Paediatrics and Adolescent Medicine, Aarhus University Hospital
Aarhus N, Aarhus N, Denmark Recruiting -
Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet
Copenhagen, København Ø, Denmark Recruiting -
Department of Paediatrics and Adolescent Medicine, Odense University Hospital
Odense, Odense C, Denmark Recruiting
Study contacts
- Principal investigator: Birgitte K Albertsen, Professor — Department of Paediatrics and Adolescent Medicine, Aarhus University Hospital
- Study coordinator: Birgitte K Albertsen, Professor
- Email: biralber@rm.dk
- Phone: +45 2022 4643
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia
This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.
-
Observatory of adults with Ph+ ALL receiving BCR-ABL1 inhibitors with chemotherapy, steroids, or monoclonal antibodies
This study follows adults with Philadelphia-positive acute lymphoblastic leukemia who are being treated with a combination of BCR-ABL1 inhibitors and other therapies to see how they fare in real-world practice.
-
Strength Training for Kids with Acute Lymphoblastic Leukemia and Lymphoblastic L lymphoma
Researchers are testing a structured strength-training program for children and teens recently diagnosed with ALL or lymphoblastic lymphoma to see if it helps with weight gain and physical function during treatment.
-
FXS0683 in relapsed or refractory blood cancers
This first‑in‑human study tests FXS0683 in adults with relapsed or refractory B‑cell lymphoma, AML, MDS, or ALL to see if it is safe, how the drug behaves in the body, and whether it shows any antitumor activity.
-
CD19-targeted CAR-T cells that make p40 for relapsed or refractory CD19-positive blood cancers
This trial will try a patient's own CD19-directed CAR-T cells engineered to produce p40 to see if they work better and last longer in adults with relapsed or refractory CD19-positive blood cancers.
-
TSLPR-CART therapy for CRLF2-R/TSLPR–expressing B-ALL in adults
This study tests a CAR T-cell treatment called TSLPR-CART in adults whose B-ALL cells overexpress TSLPR and have not responded to standard therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.